Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Standard of Care × Endocrine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Endocrine Neoplasia Type 1 3 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Obesity 1 Neuroendocrine Tumors 1 Motor Activity 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡